cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Exscientia Plc
4 own
3 watching
Current Price
$9
$0.19
(2.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,105.91M
52-Week High
52-Week High
22.99
52-Week Low
52-Week Low
4.09
Average Volume
Average Volume
0.44M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,105.91M
icon52-Week High22.99
icon52-Week Low4.09
iconAverage Volume0.44M
iconDividend Yield--
iconP/E Ratio--
What does the Exscientia Plc do?
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Read More
News & Events about Exscientia Plc.
Business Wire
2days ago
Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States. The compound is in development for immunology & inflammation...
Business Wire
2 months ago
Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country. IGNITE-AI is a Phase 1/2 trial studying EXS-21546 ('546), Exscientias A2A receptor antagonist in combination with anti-PD-1 therapy in...
Business Wire
3 months ago
Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform. The award was presented Thursday at the Prix Galien Forum in New York City. Worldwide, the Prix...
Business Wire
3 months ago
Exscientia plc (Nasdaq: EXAI) today highlighted new data aimed at enriching for patients that are more likely to respond to its precision-designed CDK7 inhibitor, GTAEXS-617 (617). The research confirmed a CDK7-specific pharmacodynamic (PD) biomarker, while revealing potential novel PD markers, and...
Frequently Asked Questions
Frequently Asked Questions
What is Exscientia Plc share price today?
plus_minus_icon
Can Indians buy Exscientia Plc shares?
plus_minus_icon
How can I buy Exscientia Plc shares from India?
plus_minus_icon
Can Fractional shares of Exscientia Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Exscientia Plc stocks?
plus_minus_icon
What is today’s traded volume of Exscientia Plc?
plus_minus_icon
What is today’s market capitalisation of Exscientia Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Exscientia Plc?
plus_minus_icon
What percentage is Exscientia Plc down from its 52-Week High?
plus_minus_icon
What percentage is Exscientia Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$9
$0.19
(2.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00